Clindamycin Phosphate Clindamycin 150 Mg while Breastfeeding
Most health expert recommend six month of exclusive breastfeeding but statics suggest that numbers are not good, almost 95% mothers start breastfeeding but this number drops to 40% in first three month and further it drops to 15% till fifth month. Sometime its due to need of medication usage. Because of these statics its important to provide good information on safety of drugs in breastfeeding so that it can be improved when possible. In this FAQ sheet we will discuss about exposure to Clindamycin Phosphate Clindamycin 150 Mg while breastfeeding. We will also discuss about common side effects and warnings associated with Clindamycin Phosphate Clindamycin 150 Mg.

What is Clindamycin Phosphate Clindamycin 150 Mg used for?


Clindamycin phosphate products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin phosphate products are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the BOXED WARNING, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin phosphate is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin phosphate and other antibacterial drugs, clindamycin phosphate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

What are the risk associated with Clindamycin Phosphate Clindamycin 150 Mg usage while breastfeeding? What precautions shall I take while using it in breastfeeding?

Clindamycin Phosphate Clindamycin 150 Mg low risk for breastfeeding
Clindamycin is the one and only active ingredient present in Clindamycin Phosphate Clindamycin 150 Mg. Clindamycin in itself is a low risk drug for lactation so it is easy to understand that Clindamycin Phosphate Clindamycin 150 Mg also comes in category of Low Risk item while breastfeeding. Below is the summary of Clindamycin in breastfeeding.

Statement of Manufacturer/Labeler about breastfeeding usage
Nursing Mothers Limited published data based on breast milk sampling reports that clindamycin appears in human breast milk in the range of less than 0.5 to 3.8 mcg/mL at dosages of 150 mg orally to 600 mg intravenously. Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora. If oral or intravenous clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition.

Clindamycin Phosphate Clindamycin 150 Mg Breastfeeding Analsys


Clindamycin while Breastfeeding

Low Risk

CAS Number: 18323-44-9

Lincosamide antibacterial. Excreted in non-significant level into breast milk. Except for few cases of enterocolitis due to disturbance of intestinal flora no other harm effects have been shown in breastfed infants. All cases spontaneously cured after discontinuation of medication. One reported case (1980) of pseudomembrane colitis in an infant whose mother was on clindamicin and gentamicin. Be aware of the possibility of false negative results of febrile infant bacterial cultures when the mother is on antibiotics and diarrheal disease due to intestinal flora imbalance. The American Academy of Pediatrics rates it as compatible with breastfeeding.


Clindamycin Phosphate Clindamycin 150 Mg Breastfeeding Analsys - 2


Clindamycin while Breastfeeding

CAS Number: 18323-44-9

Clindamycin Phosphate Clindamycin 150 Mg and breastfeeding

Clindamycin has the potential to cause adverse effects on the breastfed infant's gastrointestinal flora. If oral or intravenous clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. Monitor the infant for possible effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis. Vaginal application is unlikely to cause infant side effects, although about 30% of a vaginal dose is absorbed. Infant side effects are unlikely with topical administration for acne; however, topical application to the breast may increase the risk of diarrhea if it is ingested by the infant. Only water-miscible cream, foam, gel or liquid products should be applied to the breast because ointments may expose the infant to high levels of mineral paraffins via licking.[1]


Is Clindamycin Phosphate Clindamycin 150 Mg safe while breastfeeding

What should I do if already breastfed my kid after using Clindamycin Phosphate Clindamycin 150 Mg?

Clindamycin Phosphate Clindamycin 150 Mg is in the category of low risk, if you have already used it then its not a big deal if health and behavior of baby is good. However your health care provider shall be aware of the fact that you have used Clindamycin Phosphate Clindamycin 150 Mg so you should inform him based on your convenience.


I am nursing mother and my doctor has suggested me to use Clindamycin Phosphate Clindamycin 150 Mg, is it safe?

Clindamycin Phosphate Clindamycin 150 Mg comes in category of low risk and if your doctor is aware that you are breastfeeding it should be ok to use without much concerns.


If I am using Clindamycin Phosphate Clindamycin 150 Mg, will my baby need extra monitoring?

Not much monitoring required while using Clindamycin Phosphate Clindamycin 150 Mg


Who can I talk to if I have questions about usage of Clindamycin Phosphate Clindamycin 150 Mg in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week